Since TNF-α blockade may account for biological changes that may slow the progression of atherosclerosis in AS patients [13], the analysis of the potential influence of treatment with anti-TNF-α drugs on disease activity, systemic inflammation, MeS, and new potential CV risk biomarkers might help us to understand the effect of these biologic agents on the mechanism associated with atherosclerosis in AS patients. Here, TNF is linked to atherosclerosis.